镇心痛口服液对冠心病血栓相关分子标志物水平的影响  

Influence of Zhenxintong Oral Liquid on Thrombus-Associated Marker Levels in Coronary Heart Disease

作　　者：袁智宇[1] 袁灿宇[2] 袁海波[1] 

机构地区：[1]河南中医学院第一附属医院心内科,郑州450008 [2]河南省老干部医疗康复中心,郑州450008

出　　处：《中药新药与临床药理》2003年第4期230-233,共4页Traditional Chinese Drug Research and Clinical Pharmacology

基　　金：国家"七五"重点科技攻关项目子项目袁氏心复康方案治疗缺血性心脏病的研究(编号75-62-02-7;继续研究项目)

摘　　要：目的研究镇心痛口服液对冠心病血瘀证血栓相关分子标志物水平的影响,佐证其活血化瘀的药理作用。方法采用连续8d腹腔注射地塞米松注射液(0.25mg/kg)制备血瘀模型,第9天腹主动脉取血,测定活化部分凝血活酶时间(APTT)、抗凝血酶Ⅲ(AT-Ⅲ)、组织型纤溶酶原激活物(t-PA)、组织型纤溶酶原激活物抑制物(PAI)的水平。结果AT-Ⅲ两个治疗组与丹参滴丸组均明显高于模型对照组(P<0.05)。高剂量组APTT明显高于模型对照组(P<0.01),亦高于丹参滴丸组(P<0.05);低剂量组、丹参滴丸组APTT均高于模型对照组(P<0.05);高剂量组t-PA明显高于丹参滴丸组(P<0.01);高剂量组PAI明显低于丹参滴丸组(P<0.01),两个治疗组与丹参滴丸组PAI均明显低于模型对照组(P<0.01)。结论镇心痛口服液可改善血栓相关分子标志物水平,可使APTT时间延长,AT-Ⅲ、t-PA升高,PAI降低,纠正血液的高凝状态,恢复抗凝系统活性,预防血栓形成。Objective To provide evidence for the pharmacological action of blood-activating and blood-stasis-dissipating medicines by studying the influence of Zhenxintong Oral Liquid (ZOL) on thrombus-associated marker levels in coronary heart disease with blood-stasis syndrome. Methods Forty male Wistar rats were randomly allocated to 5 groups: normal group,model group,large-dose ZOL group,small-dose ZOL group and Compound Danshen Drip Pill(CDDP) control group. Blood-stasis models were established by peritoneal injection of dexamethasone (0.25mg·kg-1·d-1). After 8 days of treatment,levels of activated partial thromboplastin time (APTT),antithrombin -Ⅲ(AT-Ⅲ),tissue-type plasminogen activator (t-PA) and tissue-type plasminogen activator inhibitor (PAI) in blood from abdominal aorta were determined. Results AT-Ⅲlevel in the two ZOL groups and in CDDP control group was significantly higher than that in model group(P < 0.05). APTT level in large-dose ZOL group was increased significantly as compared with model group(P < 0.01) and CDDP control group(P < 0.05). Compared with model group,APTT level in small-dose ZOL group and CDDP control group was higher(P < 0.05),the difference being no significant between small-dose ZOL group and CDDP control group (P > 0.05). t-PA level was higher and PAI level was lower in large-dose ZOL group than that in CDDP control group (P < 0.01).PAI level in the two ZOL groups and in the CDDP control group was much lower than that in model group (P < 0.01).Conclusion ZOL is effective in preventing and treating coronary heart disease and its mechanism may be related to regulating hypercoagulability, activating the activity of anticoagulative system,preventing thrombus from formation and improving blood circulation by increasing the levels of APTT,AT-Ⅲand t-PA and by decreasing the level of PAI.

关 键 词：@镇心痛口服液/药理学 @血栓相关分子标志物/药物作用 冠心病 疾病模型 动物 

分 类 号：R285.5[医药卫生—中药学]